Standard BioTools Inc. Deferred Income Tax Assets, Net
Standard BioTools Inc. (LAB) had Deferred Income Tax Assets, Net of $264.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-08-05
- 2026-06-30: Deferred Income Tax Assets, Net $264.00K.
- 2026-03-31: Deferred Income Tax Assets, Net $270.00K.
- 2025-12-31: Deferred Income Tax Assets, Net $38.63M.
- 2024-12-31: Deferred Income Tax Assets, Net $138.00K.
| Period end | Deferred Income Tax Assets, Net |
|---|---|
| 2026-06-30 | $264.00K 10-Q · filed 2026-08-05 |
| 2026-03-31 | $270.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | $38.63M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $138.00K 10-K · filed 2026-03-16 |
| 2023-12-31 | $135.00K 10-K · filed 2025-03-11 |
| 2022-12-31 | $231.00K 10-K · filed 2024-03-01 |
| 2021-12-31 | $183.00K 10-K · filed 2023-03-14 |
| 2020-12-31 | $232.00K 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |